MyoPAXon focuses on efficiently generating immature, genetically correct, skeletal muscle cells from iPS (induced pluripotent stem) cells and then transplanting them into the muscles of individuals with Duchenne. Transplanted cells could help express missing proteins, such as dystrophin, and improve muscle function.
A Phase 1 study is actively recruiting.
This program is sponsored by Myogenica and has been partially funded by Parent Project Muscular Dystrophy.
For information regarding current or upcoming clinical trials please visit our Explore Clinical Trials Page.
